These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17286763)

  • 1. Pharmacovigilance studies in haemophilia.
    Ingerslev J
    Haemophilia; 2007 Mar; 13(2):121-3. PubMed ID: 17286763
    [No Abstract]   [Full Text] [Related]  

  • 2. Biovigilance and pharmacovigilance for haemophilia.
    Weinstein M; Makris M; Ludlam CA
    Haemophilia; 2010 Jul; 16 Suppl 5():17-21. PubMed ID: 20590851
    [No Abstract]   [Full Text] [Related]  

  • 3. EUHASS: The European Haemophilia Safety Surveillance system.
    Makris M; Calizzani G; Fischer K; Gilman EA; Hay CR; Lassila R; Lambert T; Ludlam CA; Mannucci PM
    Thromb Res; 2011 Jan; 127 Suppl 2():S22-5. PubMed ID: 21193110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed protocol for the evaluation of the effect of high purity factor concentrates on the immune system of hemophilia patients.
    Brettler DB
    Thromb Haemost; 1989 Sep; 62(2):811-2. PubMed ID: 2510353
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibitors, what is the risk of treatment intensity?
    Collins PW
    J Thromb Haemost; 2007 Jul; 5(7):1380-2. PubMed ID: 17445122
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic image (379). A confused man with tetraparesis and haemophilia].
    Holwerda TJ; van Geel BM
    Ned Tijdschr Geneeskd; 2008 Jul; 152(27):1518. PubMed ID: 18681361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.
    Bajwa N; Enriquez MM; Gorina E; Lemm G
    Haemophilia; 2009 Mar; 15(2):597-600. PubMed ID: 19187195
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients.
    Spira J; Plyushch O; Andreeva T; Zorenko V; Zozulya N; Velichkoi I; Zalepukhina OE; Yatuv R; Baru M
    Br J Haematol; 2012 Jul; 158(1):149-52. PubMed ID: 22490119
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies.
    Calvez T; Laurian Y; Goudemand J
    J Thromb Haemost; 2008 Feb; 6(2):390-2. PubMed ID: 18036187
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Portal hypertension in severe haemophilia.
    Woodcock BE; Lilleyman JS
    Lancet; 1983 Jun; 1(8338):1388. PubMed ID: 6134166
    [No Abstract]   [Full Text] [Related]  

  • 13. Cryoglobulinaemia in haemophilia.
    Lee CA; Kernoff PB; Peters DK
    Br Med J (Clin Res Ed); 1985 Jun; 290(6486):1947-8. PubMed ID: 3924321
    [No Abstract]   [Full Text] [Related]  

  • 14. Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge.
    Pires S; Sevivas T; Loureiro CC; Bartholomé B
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia. Judge puts limit on expert testimony from drug makers.
    AIDS Policy Law; 1997 Jan; 12(1):5. PubMed ID: 12162262
    [No Abstract]   [Full Text] [Related]  

  • 16. Hemophiliacs sue Bayer over contaminated blood products.
    AIDS Policy Law; 2003 Jun; 18(12):7. PubMed ID: 12846189
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
    Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
    Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful surgery in severe haemophilia--a two-stage replacement therapy in resource-poor countries.
    Prabhu R; Jijina F; Shetty S; Ghosh K
    Haemophilia; 2008 Sep; 14(5):1125-6. PubMed ID: 18625030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.